Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1655504-04-3
2. Icp-022
3. Orelabrutinib [inn]
4. Orelabrutinib [usan]
5. Wja5uo9e10
6. Icp022
7. 6-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-3-pyridinecarboxamide
8. 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide
9. 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide
10. 3-pyridinecarboxamide, 6-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-
11. 6-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-3-pyridinecarboxamide
12. Innobruka
13. Unii-wja5uo9e10
14. Orelabrutinib [who-dd]
15. Chembl4650321
16. Schembl16597834
17. Us9951056, Example 3
18. Gtpl10629
19. Icp-022icp-022
20. Bdbm389631
21. Ex-a3442
22. Nsc826039
23. S9600
24. Who 11190
25. Nsc-826039
26. Example 3 [wo2015048662a2]
27. Ac-36680
28. Db-091042
29. Hy-129390
30. Cs-0105163
| Molecular Weight | 427.5 g/mol |
|---|---|
| Molecular Formula | C26H25N3O3 |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 6 |
| Exact Mass | 427.18959167 g/mol |
| Monoisotopic Mass | 427.18959167 g/mol |
| Topological Polar Surface Area | 85.5 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 647 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Orelabrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Orelabrutinib, including repackagers and relabelers. The FDA regulates Orelabrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Orelabrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Orelabrutinib supplier is an individual or a company that provides Orelabrutinib active pharmaceutical ingredient (API) or Orelabrutinib finished formulations upon request. The Orelabrutinib suppliers may include Orelabrutinib API manufacturers, exporters, distributors and traders.
Orelabrutinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Orelabrutinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Orelabrutinib GMP manufacturer or Orelabrutinib GMP API supplier for your needs.
A Orelabrutinib CoA (Certificate of Analysis) is a formal document that attests to Orelabrutinib's compliance with Orelabrutinib specifications and serves as a tool for batch-level quality control.
Orelabrutinib CoA mostly includes findings from lab analyses of a specific batch. For each Orelabrutinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Orelabrutinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Orelabrutinib EP), Orelabrutinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Orelabrutinib USP).
LOOKING FOR A SUPPLIER?
